STOCK TITAN

Ionis Pharmaceuticals - IONS STOCK NEWS

Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) is a biotechnology leader pioneering RNA-targeted therapies through its antisense technology platform. This news hub provides investors and industry professionals with comprehensive updates on the company's clinical developments, strategic partnerships, and regulatory milestones.

Access real-time updates on Ionis' innovative research in neurology, cardiology, and rare diseases, including progress on therapies like Qalsody and Wainua. The page aggregates essential information including earnings reports, collaboration announcements with partners such as Biogen and AstraZeneca, and clinical trial outcomes.

Our curated collection serves as your primary source for tracking Ionis' advancements in antisense oligonucleotide development and commercialization strategies. Bookmark this page for streamlined access to verified updates about licensing agreements, patent developments, and therapeutic pipeline expansions.

Rhea-AI Summary

Ionis Pharmaceuticals (Nasdaq: IONS) announced participation in virtual fireside chats at two major investor conferences. The Bank of America Healthcare Conference is scheduled for May 12, 2021, and the RBC Capital Markets Global Healthcare Conference on May 19, 2021. The company will provide updates on presentation times and changes via its website. Live webcasts will be accessible in the Investors & Media section, with replays available within 48 hours. Ionis is recognized for its leadership in RNA-targeted therapy and has three marketed medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
conferences
-
Rhea-AI Summary

Ionis Pharmaceuticals (Nasdaq: IONS) announced its 2021 virtual Annual Meeting of Stockholders will take place on June 2, 2021, at 5:00 p.m. ET. All stockholders of record as of April 5, 2021, are invited to participate via a live webcast. The meeting will include a corporate update presented by CEO Brett P. Monia at 5:30 p.m. ET. Participants must have a 16-digit control number to join the meeting. Links for participation and further details are available on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
conferences
-
Rhea-AI Summary

Ionis Pharmaceuticals reported its first-quarter 2021 results with total revenues of $112 million amidst a net loss of $45 million (non-GAAP). The quarter saw significant advancements, including the initiation of pivotal studies for FUS-ALS and Alexander disease programs and positive outcomes for the IONIS-PKK-LRx program, indicating potential changes in standard care for hereditary angioedema. The company remains optimistic, anticipating 12 or more products on the market by 2026, currently bolstered by $2.1 billion in cash following recent financial maneuvers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
Rhea-AI Summary

Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on May 5, 2021, at 11:30 a.m. Eastern Time to discuss its first quarter 2021 financial results and provide updates on its pipeline and business progress. The event will detail the company's advancements in RNA-targeted therapy and highlight its established neurological and cardiometabolic franchises. Interested parties can access the webcast through the company's investor relations website, where a replay will also be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals has initiated a pivotal clinical study of its investigational medicine, ION373, targeting Alexander disease, a rare and fatal neurological disorder. This multi-center, double-blind study will involve up to 58 patients over a 60-week period, assessing the safety and efficacy of ION373 in reducing toxic GFAP levels in the brain. Alexander disease, caused by a genetic mutation, affects roughly one in a million births. ION373 has received orphan drug and rare pediatric disease designations from the FDA, highlighting its potential significance in the therapeutic landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals announced the pricing of $550.0 million in 0% Convertible Senior Notes due 2026, increasing from the initial $500.0 million offering. The private placement is set to close on April 12, 2021. The expected net proceeds are around $536.2 million, earmarked for repurchasing existing notes, funding convertible note hedge transactions, and other corporate purposes, including R&D. The conversion rate is 17.2902 shares per $1,000 of notes, with an initial conversion price of $57.84 per share, representing a 32.5% premium over the last sale price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
Rhea-AI Summary

Ionis Pharmaceuticals intends to offer $500.0 million of Convertible Senior Notes due 2026 in a private placement to qualified institutional buyers. An option for an additional $75.0 million is also available. Proceeds will be used to repurchase certain existing notes, cover convertible note hedge transactions, and support general corporate purposes including R&D and infrastructure expansion. The notes and associated warrants are not registered under the Securities Act and may not be sold in the U.S. without registration or an exemption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.62%
Tags
none
-
Rhea-AI Summary

Ionis Pharmaceuticals announced the initiation of a Phase 3 clinical trial for ION363, an investigational antisense medicine targeting FUS mutations in patients with FUS-ALS, a form of amyotrophic lateral sclerosis. The trial aims to demonstrate the efficacy of ION363, which has shown promise in preclinical models by reducing the production of the FUS protein. The global study will enroll up to 64 patients over a 102-week period, marking a significant step towards addressing the urgent need for treatments in this aggressive disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
-
Rhea-AI Summary

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive results from a Phase 2 clinical study of IONIS-PKK-LRx for hereditary angioedema (HAE). The treatment demonstrated a 90% mean reduction in monthly HAE attacks compared to placebo, with 92% of patients attack-free in weeks five to 17. IONIS-PKK-LRx, developed using advanced antisense technology, could potentially be a best-in-class prophylactic therapy. The study involved 20 adults, showing mild adverse events. Ionis plans to present full findings at a medical conference later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.68%
Tags
Rhea-AI Summary

Ionis Pharmaceuticals (Nasdaq: IONS) announced participation in two upcoming investor conferences:

  • 3rd Annual Stifel CNS Day on April 1, 2021
  • 20th Annual Needham Healthcare Conference on April 12, 2021

Updates on presentation details will be available on the company's website. A live webcast will be accessible in the Investors & Media section, with replays available within 48 hours. Ionis, a pioneer in RNA-targeted therapies, boasts three marketed medicines and a robust pipeline, especially in neurological and cardiometabolic fields.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences
Ionis Pharmaceuticals

Nasdaq:IONS

IONS Rankings

IONS Stock Data

4.56B
154.80M
0.83%
105.1%
8.09%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD